Compare GNS & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | WHWK |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 95.2M |
| IPO Year | 2022 | N/A |
| Metric | GNS | WHWK |
|---|---|---|
| Price | $0.65 | $2.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.6M | 191.5K |
| Earning Date | 09-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,749,894.00 | ★ $14,384,000.00 |
| Revenue This Year | $82.78 | N/A |
| Revenue Next Year | $85.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $1.39 |
| 52 Week High | $1.92 | $3.81 |
| Indicator | GNS | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 59.62 |
| Support Level | $0.53 | $2.10 |
| Resistance Level | $0.83 | $2.36 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 22.17 | 83.87 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.